Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status For The Treatment Of Cystic Fibrosis
Mpex Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Mpex orphan drug designation for levofloxacin solution for inhalation for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis.
First Step To Create Cystic Fibrosis Model Using Pigs
Cystic fibrosis is the most common genetic disease in Caucasians. The median lifespan for those with the disease is 36 years, and lung disease is the major cause of mortality. For years, scientists have studied cystic fibrosis using mice in which the cystic fibrosis gene was altered.
Cystic Fibrosis Development Better Understood
According to a report in the open-access journal PLoSComputational Biology, there is a specific molecularmechanism that could be responsible for the development of cysticfibrosis. The University of North Carolina at Chapel Hill researcherssuggest better understanding of the disease may help to develop newcorrective treatments.
5 Million Initiative To Enhance Care For Adults With Cystic Fibrosis
The Cystic Fibrosis Foundation has announced the launch of a new $5 million initiative to enhance care for the growing adult CF population. The initiative, called the Program for Adult Care Excellence (PACE), will expand the scope of adult care programs for people with cystic fibrosis.
Research Promising For Cystic Fibrosis
New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus. Led by Professor Igor Stagljar, University of Toronto scientists have identified several compounds that block activity of a key protein (exoenzymeS or ExoS).
Great Strides 2008 - Taking Steps To Cure Cystic Fibrosis, UK
Thousands of people will be taking steps to cure Cystic Fibrosis (CF) this year by taking part in a series of sponsored walks across the UK. Great Strides, sponsored by Solvay Healthcare, is a worldwide initiative to get people walking to help see off CF.
Positive Early Results For Phase 2 Clinical Trial Of VX-770 For Cystic Fibrosis
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Cystic Fibrosis Foundation Announces Positive Early Results For Phase 2 Clinical Trial Of VX-770 - An Oral Compound To Treat CF
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Cystic Fibrosis In Mice
"Drug 'could aid cystic fibrosis'" is the headline on BBC News. The article says that "widely-used antidepressants could prevent infections which shorten the lives of many cystic fibrosis patients". The report is based on the findings from a study in mice which has shed further light on the biological processes involved in the changes to the lungs caused by the cystic fibrosis mutation.
Lung Transplants Not Dangerous For Children With Cystic Fibrosis, After All - Experts Say Recent Study Was Seriously Flawed
Responding to a study published in the New England Journal of Medicine, which concluded that lung transplants were harmful for children with cystic fibrosis, articles published in the latest issue of Pediatric Transplantation refute the conclusions and argue that the highly influential research was severely flawed.